Drug Profile
Research programme: mRNA therapeutics - Kernal Biologics
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Kernal Biologics
- Class Antineoplastics; Cancer vaccines; RNA vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 14 Dec 2017 Early research in Cancer in USA (Parenteral)